Ferring BV
General
Total Cases40
Active Cases3
Patents239
Ratings
Experience
Grade
Trend
DCT
L3
B
PTAB
--
--
--
CAFC
L3
E
Analytics
Cases
Litigated Patents
Ratings Trends
Recent Dockets
Entered | Case | Description |
|---|---|---|
| 12/03/24 | REDACTED VERSION of [528] Declaration, by Finch Therapeutics Group, Inc., Finch Therapeutics, Inc., Finch Therapeutics Holdings, LLC.. (Attachments: # [1] Exhibit 13, # [2] Exhibit 14, # [3] Exhibit 15)(Metzler, Sara) (Entered: 12/03/2024) | |
| 12/03/24 | REDACTED VERSION of [527] Declaration by Finch Therapeutics Group, Inc., Finch Therapeutics, Inc., Finch Therapeutics Holdings, LLC.. (Metzler, Sara) (Entered: 12/03/2024) | |
| 12/03/24 | REDACTED VERSION of [526] Reply Brief, by Finch Therapeutics Group, Inc., Finch Therapeutics, Inc., Finch Therapeutics Holdings, LLC.. (Metzler, Sara) (Entered: 12/03/2024) | |
| 12/03/24 | REQUEST for Oral Argument by Finch Therapeutics Group, Inc., Finch Therapeutics, Inc., Finch Therapeutics Holdings, LLC. re [496] MOTION Post-Trial Motion for Enhanced Damages, Ongoing Royalty, and Pre- and Post-Judgment Interest Pursuant to Order on D.I. [490] . (Farnan, Kelly) Modified on 12/3/2024 (ceg). (Entered: 12/03/2024) | |
| 12/03/24 | Letter to The Honorable Jennifer L. Hall from Mary W. Bourke regarding request for argument - re [497] MOTION for Judgment as a Matter of Law Ferring/Rebiotix's Renewed Motion for Judgment as a Matter of Law. (Bourke, Mary) (Entered: 12/03/2024) | |
| 11/26/24 | [SEALED] DECLARATION re [526] Reply Brief, of Ingrid Petersen by Finch Therapeutics Group, Inc., Finch Therapeutics, Inc., Finch Therapeutics Holdings, LLC., Regents of the University of Minnesota. (Attachments: # [1] Exhibit 13, # [2] Exhibit 14, # [3] Exhibit 15)(Metzler, Sara) (Entered: 11/26/2024) | |
| 11/26/24 | [SEALED] DECLARATION re [526] Reply Brief, of James E. Malackowski by Finch Therapeutics Group, Inc., Finch Therapeutics, Inc., Finch Therapeutics Holdings, LLC., Regents of the University of Minnesota. (Metzler, Sara) (Entered: 11/26/2024) | |
| 11/26/24 | [SEALED] REPLY BRIEF re [496] MOTION Post-Trial Motion for Enhanced Damages, Ongoing Royalty, and Pre- and Post-Judgment Interest Pursuant to Order D.I. [490] , filed by Finch Therapeutics Group, Inc., Finch Therapeutics, Inc., Finch Therapeutics Holdings, LLC., Regents of the University of Minnesota. (Metzler, Sara) Modified on 11/27/2024 (ceg). (Entered: 11/26/2024) | |
| 11/26/24 | DECLARATION re [524] Reply Brief Declaration of Daniel M. Attaway by Ferring Pharmaceuticals Inc., Rebiotix Inc.. (Attachments: # [1] Exhibit A, # [2] Exhibit B, # [3] Exhibit C, # [4] Exhibit D, # [5] Exhibit E, # [6] Exhibit F)(Attaway, Daniel) (Entered: 11/26/2024) | |
| 11/26/24 | REPLY BRIEF re [497] MOTION for Judgment as a Matter of Law Ferring/Rebiotix's Renewed Motion for Judgment as a Matter of Law filed by Ferring Pharmaceuticals Inc., Rebiotix Inc.. (Bourke, Mary) (Entered: 11/26/2024) |